Briacell Therapeutics

Yahoo Finance • 2 months ago

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platformBria-OTS+, a novel personalized,off-the-shelf, semi-allogeneic cellular immunotherapy may address urgen... Full story

Yahoo Finance • 2 months ago

BriaCell to implement 1-for-10 reverse stock split to maintain Nasdaq listing

* BriaCell Therapeutics (NASDAQ:BCTX [https://seekingalpha.com/symbol/BCTX]) will consolidate its common shares on a 1-for-10 basis to meet Nasdaq listing requirements. * The reverse split is expected to become effective on August 25,... Full story

Yahoo Finance • 2 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel... Full story

Yahoo Finance • 2 months ago

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops nove... Full story

Yahoo Finance • 2 months ago

UCLA Health joins BriaCell's phase 3 breast cancer study

PHILADELPHIA/VANCOUVER - BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX: BCT), a clinical-stage biotechnology company with a market capitalization of $2.5 million and an overall "WEAK" InvestingPro Financial Health score of 1.36, announced... Full story

Yahoo Finance • 2 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel im... Full story

Yahoo Finance • 2 months ago

BriaCell granted New Zealand patent for cancer immunotherapy method

PHILADELPHIA/VANCOUVER - BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX:BCT), a micro-cap biotechnology company with a market value of $2.5 million, announced Wednesday it has been granted New Zealand Patent No. 785587 for its whole-cell ca... Full story

Yahoo Finance • 2 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel im... Full story

Yahoo Finance • 2 months ago

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets... Full story

Yahoo Finance • 3 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel... Full story

Yahoo Finance • 3 months ago

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.98%

Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Technology, Telecoms and Industrials sectors led shares higher while losses in the Basic Materials, Healthcare and Financials sectors led shares lower. At... Full story

Yahoo Finance • 3 months ago

Briacell stock maintains Buy rating at H.C. Wainwright on strong survival data

Investing.com - H.C. Wainwright has reiterated a Buy rating and $32.00 price target on Briacell Therapeutics (NASDAQ:BCTX), representing significant upside from the current price of $2.07. The bullish stance follows promising survival data... Full story

Yahoo Finance • 4 months ago

BriaCell Says Independent DSMB Raised No Safety Concerns Of Phase 3 Study Of Bria-IMT Plus CPI

(RTTNews) - Biotechnology company BriaCell Therapeutics Corp. (BCTX) announced Tuesday that the independent Data Safety Monitoring Board (DSMB) has completed its third scheduled safety data review of BriaCell's pivotal Phase 3 study of Bri... Full story

Yahoo Finance • 2 years ago

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction recorded.Heavily treated patient had 7 prior fa... Full story

Yahoo Finance • 2 years ago

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and... Full story

Yahoo Finance • 2 years ago

BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP. Prevail InfoWorks, Inc. to act as Contract Rese... Full story

Yahoo Finance • 2 years ago

BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR

15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment.The Bria-IMT™ combination... Full story